Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Lancet Neurology

• Publication date

  2017-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1474-4422(17)30083-2PMID 28460892
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

  2019cited by this paper
• Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.

  2016cited by this paper
• Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor

  2016cited by this paper
• Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

  2015cited by this paper
• Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

  2015cited by this paper
• OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study

  2015cited by this paper
• The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results

  2015cited by this paper
• Adherence to oral migraine-preventive medications among patients with chronic migraine

  2015cited by this paper
• Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example.

  2015cited by this paper
• Calcitonin gene-related peptide (CGRP): a new target for migraine.

  2015cited by this paper
• Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.

  2014cited by this paper
• Systematic Review of Migraine Prophylaxis Adherence and Persistence

  2014cited by this paper
• Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.

  2014cited by this paper
• CGRP as a new target in prevention and treatment of migraine.

  2014cited by this paper
• Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention

  2014cited by this paper
• Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine

  2013cited by this paper
• The International Classification of Headache Disorders, 3rd edition (beta version)

  2013cited by this paper
• In Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tracer [11C]MK-4232

  2013cited by this paper
• Defining the Differences Between Episodic Migraine and Chronic Migraine

  2011cited by this paper
• [Predisposing factors affecting drop-out rates in preventive treatment in a series of patients with migraine].

  2011cited by this paper
• Factores predisponentes al abandono del tratamiento preventivo en una serie de pacientes con migraña

  2011cited by this paper
• OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program

  2010cited by this paper
• OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial

  2010cited by this paper
• OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial

  2010cited by this paper
• Global prevalence of chronic migraine: A systematic review

  2010cited by this paper
• Topiramate Treatment of Chronic Migraine: A Randomized, Placebo‐Controlled Trial of Quality of Life and Other Efficacy Measures

  2009cited by this paper
• PACAP38 induces migraine-like attacks in patients with migraine without aura.

  2009cited by this paper
• The role of peptides in central sensitization.

  2009cited by this paper
• Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life.

  2009cited by this paper
• The International Classification of Headache Disorders

  2008cited by this paper
• Migraine prevalence, disease burden, and the need for preventive therapy

  2007cited by this paper
• Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Trial

  2007cited by this paper
• Medication–overuse headache: pathophysiological insights

  2005cited by this paper
• Chronic Daily Headache in A Tertiary Care Population: Correlation Between the International Headache Society Diagnostic Criteria and Proposed Revisions of Criteria for Chronic Daily Headache

  2002cited by this paper
• Cgrp May Play A Causative Role in Migraine

  2002cited by this paper
• Quality‐of‐Life Differences Between Patients With Episodic and Transformed Migraine

  2001cited by this paper
• Plasma levels of calcitonin gene-related peptide in chronic tension-type headache

  2000cited by this paper
• Evidence for increased plasma levels of calcitonin gene‐related peptide in migraine outside of attacks

  2000cited by this paper
• Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

  1990cited by this paper

• Effect of Erenumab on Patient-Reported Outcomes in Episodic Migraine in Asia, the Middle East, and Latin America

  2026cites this paper
• Predictors of Response to Treatment With Anti-calcitonin Gene-Related Peptide (CGRP) Antibodies in Real-World Patients With Episodic Migraine: A Two- and Four-Month Prospective Study

  2025cites this paper
• Genome-Wide Pleiotropy Analysis Identifies Shared and Opposing Pathways Influencing Coronary Artery Disease and Cancer

  2025cites this paper
• Impact of Erenumab on Comorbid Depression, Anxiety, and Sleep Quality in Migraine: A Registry for Migraine (REFORM) Study

  2025cites this paper
• Calcitonin gene-related peptide monoclonal antibody treatment for new daily persistent headache

  2025cites this paper
• Evidence-based guidelines for the pharmacological treatment of migraine

  2025cites this paper
• Erenumab for Chronic Cluster Headache

  2025cites this paper
• A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine

  2025cites this paper
• The vessel-to-neuron trigeminovascular hypothesis of migraine pathogenesis – the ‘pro’ argument

  2025cites this paper
• Clinical and Genetic Factors Associated with Non-Response to Erenumab

  2025cites this paper
• Unveiling the efficacy and safety of Erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor, in patients with chronic and episodic migraine: a GRADE-assessed systematic review and meta-analysis of randomized clinical trials with subgroup analysis

  2025influential citation
• Increased infection risk in patients on preventive CGRP-targeting therapies– a meta-analysis and clinical effect assessment

  2025cites this paper
• Kinetic Oscillation Stimulation for the Preventive Treatment of Chronic Migraine

  2025cites this paper
• Calcitonin gene-related peptide–targeted therapies for migraine

  2025cites this paper
• Usefulness of the Support Video “Talking Picture Book” for Overcoming Hesitancy to Start Galcanezumab Therapy

  2025cites this paper
• Swiss Quality of Life and Health Care Impact Assessment in a Real‐World Erenumab‐Treated Migraine Population: Results over 2 years

  2025cites this paper
• Comorbidity with fibromyalgia predicted poorer outcomes in patients with chronic migraine on flunarizine: Prospective proof-of-concept study

  2025cites this paper
• Comprehensive assessment of erenumab efficacy in participants with high‐frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study

  2025cites this paper
• Efficacy and safety of mAbs anti-CGRP/CGRP R (eptinezumab and erenumab) or atogepant in combination with onabotulinumtoxinA in refractory chronic migraine: a clinical trial protocol.

  2025cites this paper
• A Systematic Review and Meta-analysis of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies (mAbs) and Gepants for Episodic or Chronic Migraine With or Without Medication Overuse Headache

  2025cites this paper
• Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study

  2025cites this paper
• Prescription of Monoclonal Antibodies Against Calcitonin Gene‐Related Peptide for the Prophylaxis of Migraine in Austria: A Retrospective, Longitudinal Analysis of Nationwide Insurance Data

  2025cites this paper
• Efficacy and Safety of GLP‐1 and Dual GIP/GLP‐1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta‐Analysis

  2025cites this paper
• Potential benefits and possible risks of CGRP-targeted multitherapy in migraine

  2024cites this paper
• Neurobehavioral features in medication-overuse headache

  2024cites this paper
• Early Use of Erenumab vs Nonspecific Oral Migraine Preventives

  2024cites this paper
• Double-blind, randomized, placebo-controlled study to evaluate erenumab-specific central effects: an fMRI study

  2024cites this paper
• Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open‐label, multiple‐dose study

  2024cites this paper
• Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world observations of erenumab, fremanezumab and galcanezumab

  2024cites this paper
• Evidence-based preventive treatment of migraine.

  2024cites this paper
• Developments in targeting calcitonin gene-related peptide

  2024cites this paper
• Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system

  2024cites this paper
• Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison

  2024cites this paper
• Updated Canadian Headache Society Migraine Prevention Guideline with Systematic Review and Meta-analysis

  2024cites this paper
• CROATIAN GUIDELINES FOR SPECIFIC PREVENTIVE TREATMENT OF MIGRAINE WITH MONOCLONAL ANTIBODIES TARGETING CALCITONIN GENE-RELATED PEPTIDE (CGRP) (EPTINEZUMAB, FREMANEZUMAB, AND GALCANEZUMAB) OR THE CGRP RECEPTOR (ERENUMAB)

  2024cites this paper
• Research trends and hotspots in clinical trials of migraine in the past 20 years: bibliometric analysis

  2024cites this paper
• A Case Report of Chronic Migraine Lasting 30 Years and Treated with Acupuncture

  2024cites this paper
• 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for the Management of Headache

  2024cites this paper
• Metabolic Dysfunction in Idiopathic Intracranial Hypertension: Current Theories and Updates

  2024cites this paper
• Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene–related peptide monoclonal antibodies

  2024cites this paper
• An Assessment of Sex and Gender Considerations in Migraine Calcitonin Gene-Related Peptide Clinical Trials

  2024cites this paper
• Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling.

  2024cites this paper
• Effectiveness and Tolerability of Anti-Calcitonin Gene-Related Peptide Therapy for Migraine and Other Chronic Headaches in Adolescents and Young Adults: A Retrospective Study in the USA

  2024cites this paper
• Efficacy and Tolerability of Anti-CGRP Monoclonal Antibodies in Patients Aged ≥ 65 Years With Daily or Nondaily Migraine

  2024cites this paper
• Real-world Efficacy of Erenumab on Migraine-associated Symptoms and Patient-reported Satisfaction Levels: A Retrospective Study in Japan

  2024cites this paper
• Effects of Anti-CGRP Monoclonal Antibodies on Neurophysiological and Clinical Outcomes: A Combined Transcranial Magnetic Stimulation and Algometer Study

  2024cites this paper
• Reporting Quality and Risk of Bias Analysis of Published RCTs Assessing Anti-CGRP Monoclonal Antibodies in Migraine Prophylaxis: A Systematic Review

  2024cites this paper
• Activation of ATP-sensitive potassium channels triggers migraine attacks independent of calcitonin gene-related peptide receptors: a randomized placebo-controlled trial

  2024cites this paper
• Posttraumatic headache is a distinct headache type from migraine

  2024cites this paper
• CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention.

  2024cites this paper
• Drug-related side effects and adverse reactions in the treatment of migraine: a bibliometric and visual analysis

  2024cites this paper
• Neurite Damage in Patients with Migraine

  2024cites this paper
• Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis

  2024influential citation
• Headaches in adults in supplementary health: management

  2024cites this paper
• Evidence‐based review and frontiers of migraine therapy

  2024cites this paper
• Understanding the efficacy and tolerability of migraine treatment: a deep dive into CGRP antagonists

  2024cites this paper
• Revolutionizing migraine management: advances and challenges in CGRP-targeted therapies and their clinical implications

  2024cites this paper
• Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis.

  2024cites this paper
• A Risk-Difference Meta-Analysis for the Prophylactic Treatments of Chronic Migraine

  2024cites this paper
• Unlocking the potential of luteolin: A natural migraine management approach through network pharmacology

  2024cites this paper
• Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review

  2024cites this paper
• CGRP-targeted medication in chronic migraine - systematic review

  2024influential citation
• Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review

  2024cites this paper
• Alzheimer Disease Associated Loci: APOE Single Nucleotide Polymorphisms in Marmara Region

  2024cites this paper
• Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2–4 Prior Preventive Treatments Had Failed

  2024cites this paper
• Treatment Outcome After Switching From Galcanezumab to Fremanezumab in Patients With Migraine

  2024cites this paper
• Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study

  2024cites this paper
• Calcitonin Gene-Related Peptide Inhibitors in the Treatment of Migraine in the Pediatric and Adolescent Populations: A Review.

  2024cites this paper
• Induction of cGMP-mediated migraine attacks is independent of CGRP receptor activation

  2024cites this paper
• Hypersensitivity to CGRP as a predictive biomarker of migraine prevention with erenumab

  2024cites this paper
• Effectiveness and safety of pharmacological prophylaxis for chronic migraine: a systematic review and network meta-analysis

  2024cites this paper
• The evolving landscape and research trend of calcitonin gene-related peptide in migraine: A bibliometric analysis and visualization

  2024cites this paper
• Switching of monoclonal antibodies against the calcitonin gene-related peptide or its receptor in migraine. Results from a Spanish Cohort.

  2024cites this paper
• Erenumab escalation in migraine - double dose without additional benefit - a retrospective experience

  2024cites this paper
• Erenumab versus topiramate: migraine‐related disability, impact and health‐related quality of life

  2024cites this paper
• Assessment of Bone Mineral Density Over 1 Year in a Cross-Sectional Cohort of Migraine Patients Receiving Anti-CGRP Monoclonal Antibodies

  2024cites this paper
• International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine

  2024cites this paper
• Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine

  2024cites this paper
• Real-world experiences of migraine patients on Erenumab: a Kuwait single center cohort

  2024cites this paper
• Real-World Experience of Erenumab in Patients with Migraine in Germany: The SPECTRE Study

  2024cites this paper
• Pharmacotherapy approaches to migraine prevention and treatment

  2023cites this paper
• The sense of stopping migraine prophylaxis

  2023cites this paper
• Preventive CGRP-targeted therapies for chronic migraine with and without medication-overuse headache

  2023influential citation
• Calcitonin gene-related peptide (CGRP) monoclonal antibodies for migraine

  2023cites this paper
• Alopecia as an emerging adverse event to CGRP monoclonal antibodies: Cases Series, evaluation of FAERS, and literature review

  2023cites this paper
• Longitudinal differences in iron deposition in periaqueductal gray matter and anterior cingulate cortex are associated with response to erenumab in migraine

  2023cites this paper
• Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study

  2023cites this paper
• Intensive Mindfulness Meditation Reduces Frequency and Burden of Migraine: An Unblinded Single-Arm Trial

  2023cites this paper
• Observational Analysis of the Costs Associated with Acute Treatment of Breakthrough Migraine Attacks in Medicaid Patients Using Preventive Therapies

  2023cites this paper
• Remote electrical neuromodulation for migraine prevention: A double‐blind, randomized, placebo‐controlled clinical trial

  2023cites this paper
• Response to erenumab assessed by Headache Impact Test‐6 is modulated by genetic factors and arterial hypertension: An explorative cohort study

  2023cites this paper
• Effectiveness of anti-CGRP monoclonal antibodies in the preventive treatment of migraine: A prospective study of 63 patients.

  2023cites this paper
• Tolerability of pharmacological agents in the treatment of headache following brain injury: a scoping review

  2023cites this paper
• Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review

  2023cites this paper
• Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience

  2023cites this paper
• Anti-CGRP basierte Migränemedikamente – eine Übersicht der Studienlage

  2023influential citation
• Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety

  2023cites this paper
• Trial protocol for a multicenter randomized controlled trial to assess the efficacy and safety of intravenous ketamine for chronic daily headaches: the “KetHead” trial

  2023cites this paper
• The history and rationale of the development of new drugs for migraine treatment

  2023cites this paper
• Comparative Study of the Efficacy of Anti-CGRP mAbs on Migraineurs: Analysis of the First Year of Therapy, 1-Month Suspension Period, and Reprisal

  2023cites this paper